March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in your inbox.
Treatment 103: The Basics of Clinical Trials and Bio-Medical Research was the sixth in our eight-week webinar series that offers women living with HIV capacity building and training on HIV disease and treatment advocacy.
Get some great tips about traveling with HIV. Learn about packing your pills, adjusting your dosing schedule, and traveling abroad.